February 13, 2017
Evgen Pharma inks services deal with APTrans
Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. APTrans is a Cheshire-based consortium of drug development companies.